JP2014525395A5 - - Google Patents

Download PDF

Info

Publication number
JP2014525395A5
JP2014525395A5 JP2014524460A JP2014524460A JP2014525395A5 JP 2014525395 A5 JP2014525395 A5 JP 2014525395A5 JP 2014524460 A JP2014524460 A JP 2014524460A JP 2014524460 A JP2014524460 A JP 2014524460A JP 2014525395 A5 JP2014525395 A5 JP 2014525395A5
Authority
JP
Japan
Prior art keywords
population
antibody
antibodies
composition
galactosylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014524460A
Other languages
English (en)
Japanese (ja)
Other versions
JP6433786B2 (ja
JP2014525395A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/001795 external-priority patent/WO2013021279A2/en
Publication of JP2014525395A publication Critical patent/JP2014525395A/ja
Publication of JP2014525395A5 publication Critical patent/JP2014525395A5/ja
Application granted granted Critical
Publication of JP6433786B2 publication Critical patent/JP6433786B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014524460A 2011-08-10 2012-08-10 高度ガラクトシル化抗体 Expired - Fee Related JP6433786B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161521996P 2011-08-10 2011-08-10
US61/521,996 2011-08-10
US201161567364P 2011-12-06 2011-12-06
US61/567,364 2011-12-06
PCT/IB2012/001795 WO2013021279A2 (en) 2011-08-10 2012-08-10 Highly galactosylated antibodies

Publications (3)

Publication Number Publication Date
JP2014525395A JP2014525395A (ja) 2014-09-29
JP2014525395A5 true JP2014525395A5 (https=) 2015-10-01
JP6433786B2 JP6433786B2 (ja) 2018-12-05

Family

ID=47116104

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014524460A Expired - Fee Related JP6433786B2 (ja) 2011-08-10 2012-08-10 高度ガラクトシル化抗体

Country Status (9)

Country Link
US (1) US20140296490A1 (https=)
EP (1) EP2741769B1 (https=)
JP (1) JP6433786B2 (https=)
KR (1) KR20140101331A (https=)
CN (1) CN104168913A (https=)
BR (1) BR112014003110A2 (https=)
CA (1) CA2844435A1 (https=)
IL (1) IL230719A0 (https=)
WO (1) WO2013021279A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3016729B1 (fr) 2013-07-05 2020-03-25 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Matrice de chromatographie d'affinité
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) * 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR20170040132A (ko) * 2014-06-02 2017-04-12 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 Fc 단편의 제조
CN114181312A (zh) * 2014-09-10 2022-03-15 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
CN105277718B (zh) * 2015-09-29 2018-03-20 上海知先生物科技有限公司 用于恶性肿瘤相关筛查及评估的产品、应用及方法
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd
KR102718038B1 (ko) 2017-09-29 2024-10-16 온크그노스틱스 게엠베하 신생물증 및 암에 대한 위험 결정
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) * 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
CA2424977C (en) * 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
KR20030074693A (ko) * 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
CA2506629A1 (en) * 2002-11-27 2004-06-17 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
FR2861080B1 (fr) * 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
JP2008515772A (ja) * 2004-07-21 2008-05-15 グライコフィ, インコーポレイテッド Gal2GlcNAc2Man3GlcNAc2グリコフォームを支配的に含む免疫グロブリン
JP2008515813A (ja) * 2004-10-06 2008-05-15 アグリ−バイオテック ピーティーワイ リミテッド 抗体産生方法
PT1896071E (pt) * 2005-06-30 2015-07-09 Janssen Biotech Inc Métodos e composições com melhorias na atividade terapêutica
KR20140133958A (ko) 2005-10-21 2014-11-20 엘에프비 유에스에이, 인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CN101460522B (zh) * 2006-04-11 2014-07-23 弗·哈夫曼-拉罗切有限公司 糖基化抗体
EP3539981A1 (en) * 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
CN101588817B (zh) * 2006-09-10 2013-06-12 葛莱高托普有限公司 骨髓白血病来源的细胞在抗体表达中的用途
EP1985633A1 (en) * 2007-04-26 2008-10-29 LFB Biotechnologies Kit of parts for the treatment of cancer or infectious diseases

Similar Documents

Publication Publication Date Title
JP2014525395A5 (https=)
PH12020550039A1 (en) Sialyltransferases and their use in producing sialylated oligosaccharides
MY176822A (en) Anti-pd-1 antibody and use thereof
AU2012259312A8 (en) Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
WO2014125374A3 (en) Highly galactosylated anti-tnf-alpha antibodies and uses thereof
MX2014007262A (es) Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso.
WO2013096291A3 (en) Modified polypeptides for bispecific antibody scaffolds
WO2013049227A3 (en) High efficiency, small volume nucleic acid synthesis
EP4303232A3 (en) Chimeric antigen receptor and methods of use thereof
WO2016091268A3 (en) N-glycosylation
NZ717399A (en) Antibodies against csf-1r
WO2014153188A3 (en) High efficiency, small volume nucleic acid synthesis
WO2011131746A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
MX2013008903A (es) Metodos de desarrollo de variantes de terpeno sintasa.
AR083114A1 (es) Produccion de anticuerpos de fucosa baja en celulas de rata h4-ii-e
WO2012016227A3 (en) Antibodies with modified isoelectric points
PH12013500684B1 (en) Novel fucosyltransferases and their applications
WO2011150241A8 (en) Decreasing lactate level and increasing polypeptide production by downregulating ldh and pdhk expression
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
JP2011525355A5 (https=)
MX2011011075A (es) Anticuerpos especificos para cadherina-17.
MX377939B (es) Proceso para preparar un macromonomero.
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
MY150559A (en) New core shell particle multistage polymer powder, its manufacturing process and composition comprising it
PH12014500151A1 (en) Method for producing a block copolymer